AI assistant
Climb Bio, Inc. — Director's Dealing 2024
Mar 20, 2024
33982_dirs_2024-03-20_7b868b61-3fd4-41bc-8ddd-7258f9567a48.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2024-03-18
Reporting Person: Pimblett Emily (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-18 | Restricted Stock Units | $ | M | 40000 | Acquired | Common Stock (40000) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.